Johnson & Johnson (JNJ) Stock
Diversified healthcare giant with medicines devices and consumer products. Here's the price, business snapshot, and what's worth knowing about Johnson & Johnson in August 2026.
Johnson & Johnson (JNJ) is a large, diversified healthcare company operating across pharmaceuticals, medical devices and consumer health products. With a market capitalisation of about $462.11 billion, it mixes steady cash-generative consumer brands with higher-growth prescription medicines and device franchises. Investors often watch J&J for its scale, research and development pipeline, global reach and long record of dividend payments, but the company also faces patent expiries, regulatory scrutiny, litigation risk and competition that can affect earnings. Financial performance may be influenced by new product approvals, M&A activity and macroeconomic conditions. This summary is general, educational information only and not personal advice — investing carries risk and past performance is not a reliable guide to future results. Consider consulting a financial professional about suitability for your circumstances.
Why It’s Moving
JNJ is holding up on strong earnings and pipeline wins, but analysts still see room for caution.
- Shares are being driven by the company’s stronger-than-expected second-quarter results, which showed 6.6% revenue growth to $25.31 billion and helped reinforce confidence in near-term earnings momentum.
- Johnson & Johnson kept its 2026 earnings guidance at $11.60 to $11.75 per share, signaling management sees the current growth trajectory as durable but not dramatically improved from here.
- Recent product and regulatory wins, including FDA clearance for an AI-enhanced MONARCH QUEST 3 update and European approval for a TECVAYLI combination therapy, are supporting the long-term growth story in medtech and oncology.
- Offsetting the positives, analyst caution appears tied to valuation and lingering litigation overhangs, which can limit upside even after a solid earnings print.
JNJ is holding up on strong earnings and pipeline wins, but analysts still see room for caution.
- Shares are being driven by the company’s stronger-than-expected second-quarter results, which showed 6.6% revenue growth to $25.31 billion and helped reinforce confidence in near-term earnings momentum.
- Johnson & Johnson kept its 2026 earnings guidance at $11.60 to $11.75 per share, signaling management sees the current growth trajectory as durable but not dramatically improved from here.
- Recent product and regulatory wins, including FDA clearance for an AI-enhanced MONARCH QUEST 3 update and European approval for a TECVAYLI combination therapy, are supporting the long-term growth story in medtech and oncology.
- Offsetting the positives, analyst caution appears tied to valuation and lingering litigation overhangs, which can limit upside even after a solid earnings print.
Sixth Month Growth Performance
next-earnings-question
The next JNJ earnings date is expected on October 13, 2026, based on the company’s typical quarterly reporting pattern. This report should cover third-quarter 2026 results. If the date is not formally announced, it is still generally projected for mid-October.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Johnson & Johnson's stock with a target price of $224.1, indicating potential growth.
Financial Health
Johnson & Johnson is performing well with strong profits and revenue, indicating solid business operations.
Dividend
Johnson & Johnson's dividend yield of 2.02% offers a steady income for investors seeking dividends. If you invested $1000 you would be paid $20.52 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Diversified revenue base
Pharmaceuticals, devices and consumer products spread revenue sources, which can smooth cycles — though divisions face different risks and growth prospects.
R&D and pipeline
A strong research pipeline can drive future growth if approvals succeed, but clinical setbacks or regulatory delays can weigh on returns.
Global footprint
Sales across many markets provide scale and resilience, yet global regulation, litigation and supply-chain risks can affect performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
